Supply Chain Intelligence

Cartesian Therapeutics, Inc. Supply Chain

RNAC supply chain intelligence for Cartesian Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

RNAC ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

3Suppliers
3Customers
3Debt Items
20Related Chains

Cartesian Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
SHENYANG-SUNSHINE-PHARMACEUTICAL-CO-LTD SHENYANG-SUNSHINE-PHARMACEUTICAL-CO-LTD 92% The Company has paid to 3SBio an aggregate of $ 7.0 million in upfront and milestone-based payments under the 3SBio License as of March 31, 2026.
CRBU Caribou Biosciences, Inc. 72% Reciprocal relationship from CRBU graph: Reciprocal relationship from RNAC graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from RNAC graph: Reciprocal relationship from CRBU g…
FATE Fate Therapeutics, Inc. 72% Reciprocal relationship from FATE graph: Reciprocal relationship from RNAC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from RNAC graph: Reciprocal relationship from FATE g…

Cartesian Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
CRBU Caribou Biosciences, Inc. 72% Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or c…
FATE Fate Therapeutics, Inc. 72% Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely…
KYTX Kyverna Therapeutics, Inc. 72% Reciprocal relationship from KYTX graph: a have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (i) any breach of our respective repr…

Cartesian Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
RNAC-DEBT Debt stack $11.9M 90% Market cache reports total debt of $11.9M.
RNAC-DEBT-12242 Xbrl Convertible 90% xbrl convertible detail from xbrl 2016-12-31.
RNAC-DEBT-12241 Warrants outstanding: 196850 90% xbrl warrant detail from xbrl 2026-03-31.

Cartesian Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Cartesian Therapeutics, Inc..

Cartesian Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
RNAC-OWNER-SQUAREPOINT-OPS-LLC Squarepoint Ops LLC 90% 13F overlay lists Squarepoint Ops LLC as top holder; 83 tracked holders.

Cartesian Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
JBIO Jade Biosciences, Inc. 100.00 2
MYGN Myriad Genetics, Inc. 100.00 2
KYTX Kyverna Therapeutics, Inc. 100.00 2 ['customer']
CRBU Caribou Biosciences, Inc. 100.00 2 ['customer', 'supplier']
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
SNYNF Sanofi 100.00 2
FATE Fate Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
JNJ Johnson & Johnson 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
NVSEF Novartis AG 100.00 2
GRFS Grifols, S.A. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
LYEL Lyell Immunopharma, Inc. 100.00 2
AUTL Autolus Therapeutics plc 100.00 2
IPSC Century Therapeutics, Inc. 100.00 2
JAZZ Jazz Pharmaceuticals plc 50.00 2
CGEM Cullinan Therapeutics, Inc. 50.00 2
A Agilent Technologies, Inc. 50.00 2
ACET Adicet Bio, Inc. 50.00 2
BMY Bristol-Myers Squibb Company 50.00 2
View RNAC supply chain intel →

Explore the full interactive supply chain map for Cartesian Therapeutics, Inc..

Open RNAC supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map